By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

CureVac GmbH 

Paul-Ehrlich-Str. 15

Tübingen    72076  Germany
Phone: 49-7071-92053-0 Fax: 49-7071-92053-11


SEARCH JOBS


Industry
Biotechnology






Company News
Publication In EMBO Molecular Medicine Demonstrates CureVac’s Proprietary Mrna Technology Enables Antibody Mediated Therapies Against Infectious Agents, Toxins And Tumors 8/16/2017 8:52:08 AM
Publication In EMBO Molecular Medicine Demonstrates CureVac's Proprietary mRNA Technology Enables Antibody Mediated Therapies Against Infectious Agents, Toxins And Tumors 8/15/2017 7:56:08 AM
CureVac Announces Publication In The Lancet Of First-Ever Human Proof-Of-Concept Study Investigating The Safety And Immunogenicity Of A Prophylactic mRNA Vaccine 7/26/2017 6:29:27 AM
CureVac To Receive Patent Claiming The Combination Of mRNA Vaccines With Anti-PD-1 Antibodies 7/20/2017 6:59:31 AM
CureVac Expands GMP Production Capacities For RNA Products 6/26/2017 11:18:58 AM
CureVac Extends Global Intellectual Property Estate For Prophylactic mRNA Vaccines 6/13/2017 8:48:40 AM
CureVac Appoints Daniel Menichella As CEO Of CureVac Inc., The Company's U.S. Subsidiary 5/2/2017 8:53:20 AM
JPM17: CureVac Release: Biotech's mRNA Program Fails Phase II Test, Putting Spotlight on Other Biotechs Like Moderna 1/12/2017 5:45:05 AM
Study With CureVac's RNAdjuvant Technology Published In Cancer Immunology, Immunotherapy, Demonstrates Equal Responsiveness Of Blood Cells From Both Hepatocellular Carcinoma (HCC) Patients And Healthy Subjects To The RNA-Based Adjuvant 12/5/2016 6:57:53 AM
CureVac Secures An Additional $29.5 Million From Two New Investors 11/9/2016 12:54:16 PM
12345
//-->